Barrier Cell Source | Origin (cell line) | TEER (Ω cm2) | Advantages | Disadvantages | References |
---|---|---|---|---|---|
Immortalized | • canine kidney epithelial (MDCK) • human colon adenocarcinoma epithelial (Caco-2) • mouse BMEC (BEnd.3) • rat BMEC (RBE4) • human BMEC (hCMEC/D3 and hBMEC) | 40–315 compiled in [96] | • stable over numerous passages • commercially available • can be transfected to express human efflux pumps (MDCK) | • incomplete tight junctions • poor barrier function | |
Primary | Mouse, rat, porcine, bovine, human BMECs | 130–2200 compiled in [96] | • close initial resemblance to in vivo conditions | • tedious purification with low yields and batch variability • senesce after few passages • difficult to obtain healthy tissue (human) | |
PSC-derived | Mouse or human iPSC or ESC | 250–5350 | • renewable source • patient specific • physiological TEER | • require differentiation and thorough characterization |